new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first season it was in use.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045